CDDD-11-8 | m-entrepreneurship.com

Product Name :
CDDD-11-8

Search keywords :
CDDD11-8

drugId :
null

Target Vo:
Cyclin-dependent kinase 9

Target Vo Short Name :
CDK9

Moa_Name:
Tyrosine-protein kinase receptor FLT3 inhibitors

First Approval Country :

First Approval Date Filter:
null

Origin Company_Name :
University Of South Australia

Active Company_Name :
University Of South Australia

Active Indication_Name:
Leukemia, Myeloid, Acute

In Active Indication_Name:

Termination Status :

China Termination Status :

Highest Status:
Preclinical

China Highest Status:

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
Adiponectin Rabbit mAb In stock
Nimotuzumab Autophagy
ATP citrate lyase Antibody: ATP citrate lyase Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 121 kDa, targeting to ATP citrate lyase. It can be used for WB,ICC/IF,IHC-P,IP,FC assays with tag free, in the background of Human, Mouse.

Author: Betaine hydrochloride

Related Posts